Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3
Wan-Ying Lin, Jie Luo, Yin Sun, et al.
Cancer Letters (2018) Vol. 425, pp. 21-30
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Targeting STAT3 in Cancer Immunotherapy
Sailan Zou, Qiyu Tong, Bowen Liu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 723
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Yamei Hu, Zigang Dong, Kangdong Liu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 64
Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
Teodora Costea, Oana Vlad, Luminita Claudia Miclea, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 2, pp. 401-401
Open Access | Times Cited: 75
STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions
Mehrdokht Sadrkhanloo, Mahshid Deldar Abad Paskeh, Mehrdad Hashemi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114168-114168
Open Access | Times Cited: 28
Crosstalk of intracellular post-translational modifications in cancer
Zheng Wu, Rongting Huang, Yuan Liang
Archives of Biochemistry and Biophysics (2019) Vol. 676, pp. 108138-108138
Closed Access | Times Cited: 62
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Jian Huang, Biyun Lin, Benyi Li
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
Post-Translational Modifications That Drive Prostate Cancer Progression
Ivana Samaržija
Biomolecules (2021) Vol. 11, Iss. 2, pp. 247-247
Open Access | Times Cited: 33
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Dimethylcurcumin and Copper Sulfate-Loaded Silk Nanoparticles for Synergistic Therapy against Breast Cancer
Bo Zhang, Yonghong Deng, Defeng Xu, et al.
ACS Biomaterials Science & Engineering (2025)
Closed Access
The impact of dysregulation SUMOylation on prostate cancer
Kailang Li, Haifeng Wang, Bitao Jiang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
Dali Tong
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103370-103370
Closed Access | Times Cited: 26
STAT3 and Its Pathways’ Dysregulation—Underestimated Role in Urological Tumors
Maciej Golus, Piotr Bugajski, Joanna Chorbińska, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3024-3024
Open Access | Times Cited: 18
The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment
Jian‐Xuan Sun, Ye An, Jia-Cheng Xiang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13603-13603
Open Access | Times Cited: 7
A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases
Hang Hu, Huan Zhou, Defeng Xu
Chemical Biology & Drug Design (2020) Vol. 97, Iss. 4, pp. 821-835
Closed Access | Times Cited: 20
Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
Giovanni Luca Beretta, Nadia Zaffaroni
Frontiers in Chemistry (2019) Vol. 7
Open Access | Times Cited: 19
ASC-J9 Blocks Cell Proliferation and Extracellular Matrix Production of Keloid Fibroblasts through Inhibiting STAT3 Signaling
Yi‐Kai Hong, Chen-Han Wu, Yu‐Chen Lin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5549-5549
Open Access | Times Cited: 10
Effects of curcumin and ursolic acid in prostate cancer: A systematic review
Benjamin D Besasie, Achinto Saha, John DiGiovanni, et al.
Urologia Journal (2023) Vol. 91, Iss. 1, pp. 90-106
Open Access | Times Cited: 6
Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy
Hang Hu, Chong Wang, Rong Zhang, et al.
Journal of Materials Science (2020) Vol. 55, Iss. 16, pp. 6992-7008
Closed Access | Times Cited: 15
ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
Hao Tian, Fu-Ju Chou, Jing Tian, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 13
Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
Zoe R. Maylin, Radu CB Nicolescu, Hardev Pandha, et al.
Translational Oncology (2021) Vol. 14, Iss. 8, pp. 101115-101115
Open Access | Times Cited: 13
A Promising Anticancer Agent Dimethoxycurcumin: Aspects of Pharmacokinetics, Efficacy, Mechanism, and Nanoformulation for Drug Delivery
Muhammad Sohail, Wenna Guo, Xin Yang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 13
Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities
Giacomo Canesin, Agnieszka Krzyzanowska, Rebecka Hellsten, et al.
Current Opinion in Endocrine and Metabolic Research (2020) Vol. 10, pp. 36-42
Open Access | Times Cited: 14
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Changqing Xu, Yang Liu, Guisen Zhao
Current Medicinal Chemistry (2021) Vol. 29, Iss. 11, pp. 1891-1919
Closed Access | Times Cited: 12
The language of posttranslational modifications and deciphering it from proteomics data
Suruchi Aggarwal, Payal Gupta, Uma Dhawan, et al.
Elsevier eBooks (2023), pp. 109-136
Closed Access | Times Cited: 4
Dissecting multiple roles of SUMOylation in prostate cancer
Yishu Wang, Jianxiu Yu
Cancer Letters (2021) Vol. 521, pp. 88-97
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top